Physician profile
Kevin Ko
NPI 1174972129
$13,369.83
in general payments reported to CMS, 2019-2025
13 companies · $416 in 2025
The $416 reported for 2025 was more than what 90% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,455 · 2023: $6,275 · 2024: $5,224 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,003 · Food and Beverage: $3,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,002.61 |
| Food and Beverage | $3,912.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $10,146.94 | 2022-2025 | Proclaim, Eterna |
| Medtronic, INC. | $1,432.59 | 2022-2023 | Intellis Adaptivestim |
| Nevro Corp. | $507.42 | 2022-2023 | Senza |
| Relievant Medsystems, INC. | $375.06 | 2023 | Intracept |
| Boston Scientific Corporation | $273.74 | 2022-2023 | |
| Vertos Medical, INC. | $207.23 | 2024 | Mild Device Kit |
| Painteq LLC | $173.50 | 2023 | Painteq |
| Stryker Corporation | $60.51 | 2024-2025 | Optablate, Mild Device Kit |
| Biotronik Nro, INC. | $60.07 | 2024-2025 | Prospera |
| Viiv Healthcare Company | $45.54 | 2024 | Apretude |
| Depuy Synthes Sales INC. | $44.42 | 2024-2025 | Orthovisc, Monovisc |
| Bioventus LLC | $21.95 | 2024 | Gelsyn-3 |
| Urgo Medical North America, LLC | $20.86 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.